Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 68% of Public “Don't Know About HPV” Survey
May 17, 2010
- WG to Discuss Regulatory Requirements for Regenerative Medicine
May 17, 2010
- Merck Serono Begins Infertility Treatment Education Program
May 17, 2010
- Exforge to Compete with Takeda's Unisia: Mr Anderson of Novartis
May 17, 2010
- GRU to Call For Lifting on Ban on Supply of Information on Unapproved Drugs
May 17, 2010
- New JMA Leadership to Follow Former Leadership's Policies
May 17, 2010
- Janssen: Sales Up 2.7% to ¥80.5 Bil.
May 17, 2010
- Takeda Applies for Successor of Blopress in the US
May 17, 2010
- Good Control of Nocturnal Respiratory Symptoms Important in Children: Prof. Mochizuki
May 17, 2010
- Shionogi, Eli Lilly Japan to Comarket Cymbalta
May 3, 2010
- PMDA, NIBIO to Be Targeted in 2nd Round of Screening
May 3, 2010
- Novartis Confident of Being Able to Differentiate Equa from Other DPP-4 Inhibitors
May 3, 2010
- PMDA's Reform Proposal Found Insufficient by Majority of Screeners: Internal Screening
May 3, 2010
- NEW PRODUCT
May 3, 2010
- MTPC Voluntarily Refrains from Promoting 7 Products Exempted from Sanction
May 3, 2010
- Merck Serono Aims to Become Leading Company in Oncology: Dr Wein
May 3, 2010
- Chuikyo Members Call For Penalties for Fraudulent Practice
May 3, 2010
- JPMA Removes All MTPC Representatives from Executive Positions
May 3, 2010
- Japan Should Accept More Overseas Clinical Data: Mr Dunoyer
May 3, 2010
- Astellas Launches Prograf in India
May 3, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…